Aura Biosciences/$AURA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aura Biosciences
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
Ticker
$AURA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
108
ISIN
US05153U1079
Website
Aura Biosciences Metrics
BasicAdvanced
$378M
-
-$1.90
0.43
-
Price and volume
Market cap
$378M
Beta
0.43
52-week high
$11.39
52-week low
$4.35
Average daily volume
232K
Financial strength
Current ratio
11.06
Quick ratio
10.523
Long term debt to equity
11.934
Total debt to equity
14.413
Profitability
EBITDA (TTM)
-101.63
Effective tax rate (TTM)
-0.09%
Management effectiveness
Return on assets (TTM)
-32.92%
Return on equity (TTM)
-56.24%
Valuation
Price to book
2.39
Price to tangible book (TTM)
2.39
Price to free cash flow (TTM)
-3.796
Free cash flow yield (TTM)
-26.34%
Free cash flow per share (TTM)
-160.70%
Growth
Earnings per share change (TTM)
2.81%
3-year earnings per share growth (CAGR)
-22.65%
What the Analysts think about Aura Biosciences
Analyst ratings (Buy, Hold, Sell) for Aura Biosciences stock.
Bulls say / Bears say
Aura Biosciences' lead candidate, bel-sar, has demonstrated promising results in Phase 1 trials for non-muscle invasive bladder cancer (NMIBC), with four out of five patients achieving complete responses at low doses. (Investing.com)
Analysts have raised their price targets for Aura Biosciences, with Scotiabank increasing its target to $23.00, citing reduced risk in the bel-sar program and enhanced pipeline value. (Investing.com)
The company's strong financial position, with a third-quarter cash estimate of $165 million projected to sustain operations until the second half of 2026, provides a solid foundation for ongoing clinical developments. (Investing.com)
Aura Biosciences reported a quarterly adjusted loss of 52 cents per share for the quarter ended December 31, missing analyst expectations of a 44-cent loss, indicating potential financial challenges. (TradingView News)
The stock has experienced significant declines, hitting a 52-week low of $5.75, reflecting nearly a 29% drop over the past six months amid broader market challenges. (Investing.com)
Insider selling activity, including the sale of 24,992 shares by insider Los Pinos Elisabet De, may raise concerns about internal confidence in the company's future performance. (American Banking and Market News)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.
Aura Biosciences Financial Performance
Revenues and expenses
Aura Biosciences Earnings Performance
Company profitability
Aura Biosciences News
AllArticlesVideos
Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants
GlobeNewsWire·1 month ago
Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants
GlobeNewsWire·1 month ago
Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aura Biosciences stock?
Aura Biosciences (AURA) has a market cap of $378M as of June 21, 2025.
What is the P/E ratio for Aura Biosciences stock?
The price to earnings (P/E) ratio for Aura Biosciences (AURA) stock is 0 as of June 21, 2025.
Does Aura Biosciences stock pay dividends?
No, Aura Biosciences (AURA) stock does not pay dividends to its shareholders as of June 21, 2025.
When is the next Aura Biosciences dividend payment date?
Aura Biosciences (AURA) stock does not pay dividends to its shareholders.
What is the beta indicator for Aura Biosciences?
Aura Biosciences (AURA) has a beta rating of 0.43. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.